Delaware Federal Judge Rejects Challenge To Validity Of Epilepsy Drug
WILMINGTON, Del — An abbreviated new drug application (ANDA) to manufacture and market a generic version of the anti-seizure medication “Briviact” would infringe a single claim of a patent directed to...To view the full article, register now.
Already a subscriber? Click here to view full article